This trial is evaluating whether Telemedicine-Delivered Cognitive Behavioral Therapy will improve 5 primary outcomes, 3 secondary outcomes, and 3 other outcomes in patients with Type 1 Diabetes Mellitus. Measurement will happen over the course of 3 month mark (post-intervention).
This trial requires 150 total participants across 2 different treatment groups
This trial involves 2 different treatments. Telemedicine-Delivered Cognitive Behavioral Therapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Type 1 diabetes evolves from autoimmune insensitivity to insulin. Once insulin resistance sets in, glucagon secretion is reduced and diabetes is difficult to treat with antidiabetic medication alone. In addition, diabetic ketoacidosis can result from not being able to control glucagon levels adequately. Finally, autoimmune diabetes is difficult to treat with conventional medical drugs without a concurrent, perhaps more effective, autoimmune treatment. These conditions are managed with varied success in the context of a busy, outpatient tertiary medical center." - Anonymous Online Contributor
"Diabetes and its related autoimmune disorders are curable only in rare cases and only through intensive medical care and medical supervision. This therapy is not available in the Western societies." - Anonymous Online Contributor
"Diabetes can cause persistent, severe symptom patterns, including gastrointestinal discomfort, autonomic dysfunction, increased risk for cardiac disease, decreased immune system strength, damage to the microvasculature, and increased susceptibility to infection. These symptoms can be troublesome." - Anonymous Online Contributor
"Diabetes is a very prevalent condition, but its exact cause is unknown. However, it seems to be more common in individuals with a family history of diabetes and its associated complications. Autoimmune diseases seems to cause this predisposition." - Anonymous Online Contributor
"About 14 million people will have both diabetes and autoimmune disease or disease at some time in their lives. It is important to be aware that people with diabetes and autoimmune disease, and with autoimmune disease more generally, are at increased risk for cardiovascular disease." - Anonymous Online Contributor
"Autoimmunity is not only associated with type 1 diabetes but also type 2 diabetes. Insulin is the main autoantigen in type 1 diabetes and most prevalent in Caucasians. T-lymphocytes that are enriched by chemokine CCR3 are implicated in both type 1 and type 2 diabetes." - Anonymous Online Contributor
"Teleconsultation in combination with usual treatment may be more effective in improving depressive mood and treating the pain of patients with diabetes, as well as in improving diabetes-related quality of life." - Anonymous Online Contributor
"Diabetes mellitus and autoimmune disorders are increasingly of concern as public health problems. New approaches such as novel therapeutic options need to be provided in terms of prevention and treatment. Diabetes and other autoimmune disorders are expected to become an emerging global problem in conjunction with an ongoing ageing population with the subsequent increase in incidence of diabetes." - Anonymous Online Contributor
"Telemedicine CTT for the dissemination of cognitive behavioral therapy is a useful, potentially cost-effective approach to treatment of mood and anxiety disorders. The use of a phone-based system offers two advantages: first, patients receiving CBT have access to a trained therapist, and second, the patient-therapist relationship is preserved, reducing the need for face-to-face contact. Further research is needed to evaluate the effectiveness of using the teleconsultation model to disseminate CBT." - Anonymous Online Contributor
"While a greater proportion of patients in the intervention group had improved health-related quality of life, patient satisfaction, and health care use compared with the control group, there was no statistically significant difference in HbA1c levels between the two groups. [Power]: 75% and 75% (primary and secondary outcome). [Consensus Statement (2007): Clinical Practice Action to Treat Diabetes (TAD) in Primary Care Practice. Consensus Statement of the North American College of Physicians Committee on CABG & EVCAB and North American Society for Cardiovascular Patient Care: American College of Cardiology/American Heart Association. Clin Cardiovasc Thromb. 2007 Nov;14(3):253-9." - Anonymous Online Contributor
"Diabetes, auto-antibody profiles, and HLA association are more common in diabetic families than in matched control families. Diabetes itself can predispose to autoimmune diseases, with and without HLA associations." - Anonymous Online Contributor
"Clinical trials for diabetes should be targeted to patients with well defined clinical features and in a position to benefit from any potential benefit. Recent findings of this first pilot study indicate that a significant proportion of all patients may be eligible for a clinical trial and that most of these patients would benefit from participation. Consideration of clinical research should routinely be part of the management of diabetes." - Anonymous Online Contributor